Adults with persistently raised triglycerides or mixed hyperlipidaemia may be prescribed Lopid when diet and lifestyle measures alone are insufficient. Lopid is an antihyperlipidaemic tablet used to…
Adults with persistently raised triglycerides or mixed hyperlipidaemia may be prescribed Lopid when diet and lifestyle measures alone are insufficient. Lopid is an antihyperlipidaemic tablet used to improve an abnormal lipid profile and reduce complications linked with severe triglyceride elevation.
Lopid belongs to the fibrate group of antihyperlipidaemic treatments. It is used in adults with hyperlipidaemia, hypertriglyceridaemia, or a mixed lipid pattern involving raised triglycerides and cholesterol. The treatment goal is to improve the lipid profile and reduce exposure to atherogenic blood fats.
Lopid is an oral tablet belonging to the fibrate group of antihyperlipidaemic treatments. It is used in adults with hyperlipidaemia, hypertriglyceridaemia, or mixed raised triglycerides and cholesterol. The dose is decided individually according to age, other medicines, health conditions, and response to follow-up blood tests.
Lopid belongs to the fibrate group of antihyperlipidaemic treatments. It is used in adults with hyperlipidaemia, hypertriglyceridaemia, or a mixed lipid pattern involving raised triglycerides and cholesterol. The treatment goal is to improve the lipid profile and reduce exposure to atherogenic blood fats.
Persistently severe hypertriglyceridaemia can increase the risk of acute pancreatitis, an inflammatory condition affecting the pancreas. Lipid treatment may also form part of long-term cardiovascular risk management when triglycerides remain elevated despite dietary changes.
Prescribers may consider Lopid for adults with:
The treatment plan should also address secondary causes of abnormal lipids. Poorly controlled diabetes, hypothyroidism, excess alcohol intake, kidney disease, and some medicines can worsen hyperlipidaemia.
Lopid is not a treatment for a single cholesterol reading. Prescribers assess the complete lipid profile, medical history, diet, weight, blood glucose, thyroid status, kidney function, and cardiovascular risk.
The dose of Lopid is decided individually, taking age, other medicines, and health conditions into account. The prescriber also considers the severity of hypertriglyceridaemia, kidney function, liver function, and the response shown by follow-up blood tests.
Use the tablets according to the prescribed schedule:
Do not change the dose because a cholesterol result improves. Lipid treatment is adjusted using repeat blood tests and the person’s wider cardiovascular risk.
Avoid crushing or chewing a tablet unless the prescribing clinician has specifically confirmed that doing so is suitable for the exact formulation. Tablets should remain intact when the formulation is intended to deliver the medicine in a controlled way.
Dietary treatment remains relevant during therapy. Reducing excess alcohol, replacing saturated fats with unsaturated fats, increasing fibre where appropriate, and managing diabetes can support improvement in triglycerides and cholesterol.
Treatment should be avoided in people with:
Important medicine interactions include:
Lopid is not suitable for everyone. Lopid is not for you if you have severe liver or kidney disease, active gallbladder disease, or a previous serious reaction to gemfibrozil. A history of gallstones, unexplained right-upper abdominal pain, or previous bile-duct disease should be discussed before treatment begins.
Lopid can cause digestive symptoms, including dyspepsia, nausea, diarrhoea, or abdominal pain. These effects may be mild, yet persistent abdominal discomfort deserves assessment because abdominal pain can also signal gallbladder or pancreatic disease.
Other possible reactions include:
Seek urgent medical attention for sudden facial or throat swelling, breathing difficulty, severe widespread rash, marked muscle weakness, dark urine, yellowing of the skin, or severe upper abdominal pain. These symptoms may indicate a serious allergic, muscular, hepatic, gallbladder, or pancreatic reaction.
Digestive symptoms are easier to assess when their timing is recorded. Note whether discomfort appears soon after a dose, after meals, or continuously through the day. That detail can help the prescriber decide whether the symptom is medicine-related or requires investigation for another cause.
Liver function, kidney function, and lipid results may be monitored during longer treatment. The exact testing schedule depends on the patient’s medical history and any other medicines being used.
Fibrates influence peroxisome proliferator-activated receptor alpha, commonly called PPAR-alpha. This regulatory pathway affects genes involved in fatty-acid oxidation, lipoprotein lipase activity, and the removal of very-low-density lipoprotein particles from the blood.
The practical effect can include:
Statins and fibrates do not work through the same primary pathway. Statins focus mainly on reducing hepatic cholesterol synthesis and lowering LDL cholesterol. Fibrate therapy focuses more strongly on triglyceride-rich lipoproteins.
Several habits can reduce the benefit of lipid treatment:
The choice between lipid-lowering approaches depends on the dominant abnormality, cardiovascular risk, kidney and liver function, and the person’s existing medicines.
| Treatment category | Main lipid target |
|---|---|
| Lopid and other fibrate therapy | Triglycerides and triglyceride-rich lipoproteins |
| Statin therapy | LDL cholesterol and atherosclerotic risk |
| Combination lipid treatment | More than one lipid abnormality when clinically justified |
Atorvastatin, pravastatin, and rosuvastatin are statins used mainly to lower LDL cholesterol. Fenofibrate is another fibrate used for triglyceride-focused treatment. A prescriber may select a statin when LDL cholesterol is the main concern, while a fibrate may be considered when triglycerides remain very high.
Combining a fibrate with a statin requires careful clinical judgement. The combination can increase the risk of muscle toxicity, and the choice of fibrate matters. A person should not add, stop, or exchange lipid medicines without a specific prescribing decision.
The right treatment cannot be selected from the triglyceride number alone. Severe hypertriglyceridaemia, diabetes, kidney impairment, thyroid disease, and previous cardiovascular disease can all alter the treatment plan.
In clinical practice, prescribers usually look for the reason behind raised triglycerides before selecting treatment. A very high result may require rapid attention to alcohol intake, diabetes, diet, thyroid function, kidney disease, and interacting medicines.
A doctor will also distinguish between the main lipid problem and the patient’s broader cardiovascular risk. A person with high LDL cholesterol and modestly raised triglycerides may need a different strategy from someone with severe hypertriglyceridaemia and a pancreatitis risk.
Treatment response is judged through follow-up testing rather than symptoms. High cholesterol and triglycerides commonly produce no noticeable warning signs, so feeling well does not show that the lipid abnormality has resolved.
One practical point often missed is the effect of alcohol. Even a short period of heavy alcohol intake can raise triglycerides substantially, making a treatment appear less successful than it might be under stable conditions.
The best time is the schedule selected by the prescriber for the individual treatment plan. NICE lipid-management guidance published in 2023 supports taking medicines consistently and reviewing adherence alongside repeat lipid testing. Take each dose at the prescribed time, and do not move it to a different part of the day without clinical advice.
Pregnancy and breastfeeding require a specific assessment before Lopid is used. The EMA approach to medicine safety, reflected in its 2023 regulatory guidance, is to weigh maternal benefit against potential infant or fetal risk for lipid-lowering treatments. Do not start, continue, or restart therapy during pregnancy or breastfeeding unless the responsible prescriber has made that decision.
Severe muscle weakness, intense muscle pain, dark urine, yellow skin, facial swelling, breathing difficulty, or severe upper abdominal pain require urgent medical assessment. The HPRA medicine-safety framework published in 2024 treats these types of symptoms as possible signs of serious hepatic, muscular, allergic, or biliary reactions. Do not take another dose while seeking urgent advice if a serious reaction is suspected.
Severe liver disease, severe kidney disease, or active gallbladder disease can rule out treatment. The EMA’s 2023 principles for lipid-lowering medicine assessment identify organ function and gallbladder history as important factors in treatment selection. A history of gallstones should be disclosed before prescribing, even if symptoms have stopped.
Do not split, crush, or chew the tablet unless the prescriber or dispensing pharmacist has confirmed that the exact formulation can be altered. FDA tablet-administration guidance from 2022 explains that changing a tablet can affect how the medicine is released or absorbed. Swallow the tablet intact with water when that is the prescribed method.
Yes, abdominal pain and dyspepsia can occur during treatment. WHO pharmacovigilance principles published in 2023 support assessing persistent or severe symptoms rather than assuming they are minor digestive effects. Severe pain, pain under the right ribs, vomiting, fever, or yellowing of the skin needs prompt medical assessment because gallbladder, liver, or pancreatic problems may present with abdominal symptoms.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Long-term lipid management aims to reduce exposure to atherogenic lipoproteins and lower the chance of cardiovascular complications. Raised triglycerides often occur alongside obesity, insulin resistance, diabetes, low HDL cholesterol, or raised LDL cholesterol, so treatment is usually part of a broader risk-reduction plan.
Clinical evidence has shown cardiovascular benefit from improving selected lipid abnormalities in appropriate patients. The size of benefit depends on the starting lipid profile and the person’s wider risk factors. Lowering triglycerides alone does not remove the risk created by smoking, high blood pressure, diabetes, or raised LDL cholesterol.
Lopid should be viewed as one part of a continuing plan that may include:
The goal is not simply a better laboratory number. The goal is a lower long-term risk of heart attack, stroke, pancreatitis, and other complications linked with uncontrolled lipid disorders.
Based on 4 reviews
I had been dealing with high triglycerides for several months. The first week brought mild indigestion, so I started taking the tablets at the prescribed time with water. The stomach symptoms settled, but the improvement only became clear after my follow-up blood test.
Several months 4 Nov 2026My triglycerides were high alongside poorly controlled diabetes. Lopid was added while my diet and glucose treatment were reviewed. I did not notice a physical change, which made it easy to forget doses, so I used a weekly medicine organiser.
9 Oct 2026I developed abdominal discomfort after starting treatment and initially assumed it was ordinary indigestion. It continued for several days, so I contacted the prescriber and had further checks. The experience made me take warnings about persistent pain more seriously.
Several days 16 Oct 2026The tablets fitted into my morning and evening routine, although the diet changes were harder than the medicine. My triglycerides improved at review, but my clinician continued monitoring the full lipid profile rather than relying on one result.
24 Oct 2026
